EGFR and non-small cell lung carcinoma: However, several studies such as CTONG 1103 have treated patients with EGFR-mutated resectable NSCLC with a 42-day regimen of neoadjuvant therapy and achieved an ORR of only 54.1%–58.3% (Zhong et al., 2015; Zhong et al., 2019; Zhang et al., 2021).